OmniAb provides industry-leading transgenic animal-based platforms and AI-powered technologies to enable pharmaceutical partners to discover fully human antibodies and other next-generation biologics. Its technologies are widely adopted by over 90 biopharma companies globally. Clinical results pertain to partner programs using the platform rather than direct development by OmniAb itself.
Over 90 biopharmaceutical companies and research institutions worldwide license or collaborate with OmniAb for their drug discovery effortsPartnership with mAbsolve Ltd. for Fc-silencing STR technology integration into antibodies generated via the platformExtensive network of CROs experienced in characterization/bioinformatics/cell line development/GMP manufacturing using its technologies
03
Financials
Market cap
$704.5M
Total revenue
$18.7M
Enterprise value
$658.4M
Beyond the preview
Go deeper on OmniAb.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on OmniAb.